Foghorn Therapeutics Advances Oncology Pipeline with New Trials
Company Announcements

Foghorn Therapeutics Advances Oncology Pipeline with New Trials

The latest update is out from Foghorn Therapeutics ( (FHTX) ).

Foghorn Therapeutics is making strides in oncology with its Gene Traffic Control Platform, evidenced by the recent dosing of its first patient with the SMARCA2 inhibitor FHD-909 in Phase 1 trials focused on NSCLC. The company anticipates key data from its AML study with FHD-286 by year-end and plans to kickstart IND-enabling studies for its CBP degrader program. With a robust financial position of $267.4 million, Foghorn is well-equipped to advance its pipeline into 2027, aiming to transform treatments for a variety of cancers.

See more insights into FHTX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFoghorn Therapeutics Reports Third Quarter Highlights
TheFlyFoghorn Therapeutics reports Q3 EPS (31c), consensus (44c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App